Category: ACN Newswire

HONG KONG, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - On 27 March, Ausnutria Dairy Corporation Ltd (Stock Code: 1717.HK, hereinafter referred to as "Ausnutria" or the "Company") officially released its 2025 annual results announcement. According to the announcement, Ausnutria achieved revenue of approximately RMB7.488 billion in 2025, representing a year-on-year increase of 1.2%. The Company recorded EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) of approximately RMB518 million. Excluding the impact of one-off non-recurring items, core EBITDA reached approximately RMB616 million, demonstrating the Company's steady progress in navigating industry cycles. In 2025, driven by the dual engines of Family Nutrition and International Business, Ausnutria achieved resilient revenue growth while making significant breakthroughs in product category mix and regional market expansion. Notably, the international business of Kabrita has approached the RMB1 billion mark, with a compound annual growth rate exceeding 50% for three consecutive years, as its new global business ecosystem continues to take shape at an accelerated pace.Over the past year, the global economy has been marked by complexity and volatility, with heightened uncertainties arising from geopolitical tensions, inflation and exchange rate fluctuations. Compounded by intensifying competition amid a contracting domestic infant milk formula (IMF) market, the industry has faced multiple severe challenges. Against this backdrop, Ausnutria has maintained its strategic resolve, deepening its core strengths. The Company's international business has continued to unleash its growth momentum, while the Family Nutrition business has flourished across multiple fronts. Market share in core milk powder categories has steadily increased, and the level of refined management has improved significantly. Through these multi-dimensional efforts to enhance operational resilience, Ausnutria has laid a solid foundation for its long-term development.Kabrita International Business Approaches RMB1 Billion Mark with CAGR Exceeding 50% for Three Consecutive YearsIn 2025, Ausnutria further accelerated its internationalization efforts, continuously strengthening its comprehensive capabilities in global supply chain deployment, localised operations and digital collaboration, driving continued explosive growth in its overseas business. During the reporting period, revenue from the international business of Ausnutria's goat milk formula brand Kabrita recorded a year-on-year increase of 50.7% to approximately RMB974 million, making it the first infant goat milk formula brand from a Chinese dairy company to approach RMB1 billion in overseas sales. With a compound annual growth rate exceeding 50% for three consecutive years, the growing contribution of overseas markets has become increasingly prominent.Revenue from the Middle East market recorded a year-on-year increase of 65.5%, accounting for 45.7% of total overseas revenue and maintaining its position as Ausnutria's largest overseas sales market. Growth in this region was primarily driven by strong performance across established markets including Saudi Arabia, the UAE, Qatar and Kuwait, where the Company strengthened its promotion through medical and healthcare professional channels, continuously enhancing the medical endorsement of its goat milk formula products in these markets. Saudi Arabia delivered a particularly outstanding performance, leveraging deep collaborations with local maternity, infant care and medical institutions to effectively boost consumer acceptance and market penetration. Notably, Kabrita was awarded the "Fastest Growing Brand" accolade by Nahdi, the largest pharmacy retailer in the country. The newly entered Oman market in 2025 also exceeded expectations, injecting fresh momentum into the Company's growth.Revenue from the Commonwealth of Independent States (CIS) market recorded a year-on-year increase of 40.1%, accounting for 23.9% of total overseas revenue. As one of the Company's earliest overseas markets, the CIS market has achieved full product category coverage for Kabrita, encompassing infant formula, cereals, fruit purees, biscuits and more, comprehensively meeting the diverse consumer needs in the region. Through its "360° Omni-channel Marketing" strategy and "DTC Loyalty Program", the Company has engaged target consumers in a distinctive manner, building high value-added brand recognition and continuously consolidating and strengthening its core competitiveness in this market.Revenue from the North American market recorded a year-on-year increase of 39.5%, accounting for 22.2% of total overseas revenue. In 2025, Kabrita successfully entered Walmart, the largest retailer in the United States, and has now expanded into 780 stores, progressively developing both online and offline channels to reach a broader consumer base. In the newly entered Canadian market, the Company has been deepening its presence through the core Walmart channel while gradually building momentum on Amazon.In addition, the Company achieved 100% year-on-year growth in the Southeast Asian market by strengthening product differentiation through formula upgrades, with a particular focus on advancing digital community engagement and deepening collaboration with e-commerce channels and local platforms.Family Nutrition Achieves Steady Growth, Building Multi-dimensional Foundations for Future SuccessAs the Company's continuously nurtured "second growth curve" business, Ausnutria's nutrition products business achieved steady growth in 2025, with revenue recording a year-on-year increase of 5.2%. According to the announcement, this revenue growth was primarily attributable to continuous innovation in star probiotic strains and products, precise execution of channel strategies, and the sustained release of brand equity.Research-driven brand development. Ausnutria entered into a six-year strategic partnership with Jiangnan University, establishing the Joint Innovation Centre for Microecology and Functional Dairy as well as the Collaborative Innovation Centre for Probiotics, embarking on a new chapter of full-chain innovation collaboration. In the B2B segment, the Company achieved several key breakthroughs in probiotic strains: Bifidobacterium longum subsp. infantis YLGB-1496 was approved by the National Health Commission (NHC) for inclusion in the list of edible bacterial strains for infants and young children. With this approval, Ausnutria now possesses two nationally approved infant probiotic strains, earning its distinction as the "double champion" in China's infant probiotics field. Additionally, the independently developed Bifidobacterium animalis subsp. lactis CP-9 obtained the U.S. FDA GRAS (Generally Recognized as Safe) certification, marking Ausnutria's achievement of world-leading standards in research innovation and quality control. The continuous breakthroughs in strain technology provide strong and enduring core momentum for brand development. In the B2C segment in 2025, NC Stomach Care Powder and NC Nasal Comfort Probiotics maintained top rankings in category search popularity on Xiaohongshu. As certified by Euromonitor International, NC was awarded the title of "No.1 in National Sales of Australian Brand Nasal Sensitivity Probiotics".Innovation in response to emerging consumer demands. Bio(R) (Baoyichang(R)) Active Lactic Acid Bacteria Powder introduced a mini space capsule design, setting new aesthetic standards for probiotic products. Yili Changshi Probiotics, formulated with the patented BL-99 strain, achieved a top position on e-commerce bestseller lists. Diversified dosage form solutions, including instant-dissolve powder and micro-effervescent tablets, have effectively enhanced the product competitiveness of business partners. Throughout the year, NC launched 17 new products including G13 Growth Capsules and Sleep Well Probiotics, building a precision nutrition matrix covering gastrointestinal health, nasal sensitivity, sleep, growth, eye and brain health, liver and kidney health, and women's health.Channel upgrades fueling business development. The Company continued to deepen its presence in pharmaceutical channels, achieving simultaneous growth in both scale and pace of expansion. Collaboration with leading platforms was further strengthened, driving rapid growth in private domain e-commerce. The application of star probiotic strains was reinforced, enabling continued expansion of brand clientele. The Company also made breakthroughs in overseas market reach by expanding into European and North American markets. NC achieved steady growth on mainstream e-commerce platforms such as Tmall and JD.com, with the Stomach Care and Nasal Comfort product lines becoming leading brands in the cross-border health supplement category through channels such as Sam's Club and China Duty Free (CDF). The Company partnered with XKA and Fengxiangjia to develop its private domain presence, building an incremental online growth matrix. Offline, the Company consolidated its core client base, expanded into potential customer segments, and achieved initial results from pharmaceutical channel pilot programmes, laying a solid foundation for diversified business development.Domestic Milk Powder Business Steadily Increases Market Share, Solidifying Core FundamentalsChina's infant milk formula (IMF) industry is currently undergoing a period of deep structural adjustment, facing multiple pressures including overall market contraction, intensifying competition, and channel transformation, while birth rate fundamentals and channel structure remain under sustained pressure. During the reporting period, Ausnutria solidified its core fundamentals amid cyclical industry challenges, achieving steady growth in market share for its self-owned milk powder brands and recording overall revenue of approximately RMB5.321 billion.According to NielsenIQ and Syntun data, Kabrita's market share in China's all-channel Goat Milk formula market increased by 2.6 percentage points to 30.2% in 2025. NielsenIQ data further shows that Kabrita has maintained a market share of over 60% in China's imported infant and child goat milk formula market for eight consecutive years (2018–2025). Confirmed by Frost & Sullivan research, Kabrita continues to hold the undisputed position of "No.1 in Global Goat Milk Formula by Both Sales Volume and Sales Value", underscoring its unassailable market leadership.NielsenIQ data also indicates that the Company's cow milk formula business has stabilised its market share, marking the full conclusion of the transitional impact arising from earlier internal integration and channel restructuring. As of the date of this announcement, Ausnutria's Hyproca brand has been awarded dual certifications by iiMedia Research, namely "No.1 in National Sales of Comprehensive Nutrition Infant Formula in 2025" and "Pioneer of Comprehensive Nutrition Infant Formula in China", marking the third consecutive year that Hyproca has topped the comprehensive nutrition formula sales rankings.In 2025, the Company successfully completed the registration of 24 products across 8 series under the New National Standard 2.0 and launched 6 infant formula products across 2 series as well as 25 modulated milk powder products, offering consumers a wider range of functionalised and differentiated product choices. Kabrita was awarded the First Prize for Technological Advancement at the Science and Technology Awards for its research and development project titled "Research and Development of an Infant Formula that Supports Immune Regulation and Alleviates Immune Stress". Meanwhile, Hyproca 1897 was recognized as a "100% Quality Product", with the Company's product strength receiving authoritative endorsement.Lean Management Enhances Quality and Efficiency, Organizational Vitality Continues to FlourishIn 2025, Ausnutria continued to solidify the foundation for long-term development and achieve simultaneous improvements in organizational efficiency and development quality through a series of initiatives, including fully leveraging the momentum of its global supply chain, strengthening internal management effectiveness, establishing the cultural foundation for global collaboration, advancing the construction of its digital intelligence system, and enhancing its sustainable development governance capabilities.Global supply chain momentum unlocks new value growth opportunities. Following Ausnutria's acquisition of Amalthea Group, a Dutch goat cheese company, the Company achieved self-sufficiency in goat whey, a core ingredient for goat milk formula, while also adding cheese to its product portfolio. In 2025, the Company's Goat Cheese business recorded revenue of RMB1.006 billion, further deepening the moat of its internationalization strategy. Concurrently, the Company launched four major goat-based ingredients: goat cheese protein hydrolysate, hydrolyzed goat whey protein powder, goat lactoferrin, and goat colostrum powder. Several of these core goat milk ingredients achieved breakthroughs in commercially viable global applications from scratch, opening up new avenues for value creation for the Company.Internal management effectiveness strengthened to systematically drive sound operations. In 2025, the Company's inventory impairment provisions decreased by 0.9 percentage points year-on-year. Overall asset turnover ratio continued to improve, with inventory turnover days declining by 16 days. The Company continued to advance refined cost management, achieving a notable optimization in its expense ratio, which decreased by 1.4 percentage points year-on-year, with the selling and marketing expense ratio declining by 2.4 percentage points year-on-year.Global systematization of business philosophy to strengthen global strategic synergy. To better align with the pace of business development and reinforce Ausnutria's "one global chessboard" strategic approach, the Company officially released the "Ausnutria Business Philosophy (Overseas Edition)". Co-created through multiple rounds of in-depth discussions among over 60 core managers from Ausnutria's global operations, this business philosophy systematically establishes the core values and management principles for Ausnutria's overseas business. It serves as a tailor-made cultural compass and behavioral benchmark for overseas teams, laying a solid ideological foundation for future business development.Full-chain digital intelligence upgrade, empowering both business and management. The Company has introduced digital intelligence across all stages, from demand research and process design to implementation and execution, enabling traceable decision-making, monitorable processes and quantifiable results. Through the establishment of a data middle platform, intelligent analytical models and other tools, data has become the core enabler for optimising management and supporting business operations, fundamentally safeguarding the sustained and healthy development of the business.Upholding sustainable development principles and actively fulfilling corporate social responsibility. The Company has always adhered to a long-term vision for sustainable development, actively responding to the United Nations Sustainable Development Goals. Centred on three strategic pillars "Better Life, Better Nutrition, Better Environment” the Company has embedded sustainability principles into its operational management framework and across all stages of the value chain. In 2025, Ausnutria organized the "Hyproca Gesang Flower Charity Campaign" for the ninth consecutive year and launched the "Kabrita Care · Worry-free Pregnancy" maternal mental health charity initiative, among other activities. The Company has continued to contribute its corporate strengths in areas such as rural revitalization, education support, national nutrition enhancement and natural disaster relief.In 2025, with the support of consumers, shareholders and all sectors of society worldwide, together with the dedicated efforts of all employees, the Company successfully navigated the multiple challenges arising from economic and industry cyclical adjustments. Looking ahead to 2026, the internal and external environment remains complex and challenging. Ausnutria will continue to put consumers at the center, stay anchored to its operational objectives, accelerate systematic organizational development, drive growth through innovation, enhance efficiency through management excellence, and deliver superior products and performance to reward the trust of all stakeholders, in pursuit of long-term sustainable and high-quality development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月28日 - (亞太商訊 via SeaPRwire.com) - 3月27日，澳優乳業股份有限公司（股份代號：1717.HK，以下簡稱「澳優」或「公司」）正式發布2025全年業績公告。公告顯示：2025年，澳優實現營業收入約人民幣74.88億元，同比增長1.2%；實現EBITDA（息稅折舊及攤銷前利潤）約人民幣5.18億元；剔除一次性非經常性項目的影響，實現核心EBITDA約人民幣6.16億元，以穩健的步伐穿越行業週期。2025年，澳優通過全家營養與國際業務的雙輪驅動，實現營收韌性增長，幷在品類結構與區域市場拓展上取得突破。其中，佳貝艾特國際業務規模已接近10億元，連續三年複合增長率超過50%，全球業務新生態正加速成型。過去一年，全球經濟複雜多變，地緣政治、通脹及匯率波動等不確定性加劇，疊加國內嬰配粉市場减量競爭日趨激烈，行業面臨多重嚴峻挑戰。在此背景下，澳優始終保持戰略定力，深耕核心優勢，國際業務勢能持續釋放，全家營養業務多點開花，奶粉核心品類市占率穩步提升，精細化管理水平顯著提高，從多維度提升經營韌性，築牢公司長遠發展根基。佳貝艾特國際業務接近10億規模，連續三年複合增長率超50%2025年，澳優進一步加快國際化步伐，不斷增强全球供應鏈布局、本地化運營、數字化協同等綜合硬實力，驅動海外業務繼續取得爆發式增長。公告期內，澳優羊奶粉佳貝艾特（Kabrita）國際業務收入實現同比增長50.7%至約人民幣9.74億元，成為中國乳企第一個在海外市場銷售額接近10億規模的嬰配羊奶粉品牌，連續三年複合增長率超50%，海外市場的增長貢獻持續凸顯。中東市場營收同比增長65.5%，占海外總營收45.7%，保持澳優海外最大銷售市場的地位。該區域增長主要得益于沙特、阿聯酋、卡塔爾、科威特等成熟市場全面開花，通過强化醫療專業渠道推廣，持續提升公司羊奶粉在這些市場的醫學認可度。其中沙特市場表現亮眼，依托與當地母嬰及醫療機構的深度合作，有效提升消費者接受度與市場滲透率，幷斬獲當地最大的藥房零售商Nahdi「增長最快品牌」榮譽。2025年新開拓的阿曼市場表現超預期，為增長注入新動能。獨聯體市場營收同比增長40.1%，占海外總營收23.9%。作為公司首批布局的海外市場，獨聯體市場已實現佳貝艾特全品類覆蓋，包含嬰幼兒配方奶粉、穀物、果泥、餅乾等，充分滿足當地多元消費需求。通過「360°全域營銷」與「DTC忠誠計劃」、以獨特方式觸達目標人群，構建高附加值品牌認知，實現公司在該市場的核心競爭力持續鞏固與提升。北美市場營收同比增長39.5%，占海外總營收22.2%。2025年，佳貝艾特成功進駐美國最大零售商沃爾瑪，目前已進入780家門店，有序拓展綫上及綫下渠道，覆蓋更廣泛消費群體。新進入的加拿大市場，深耕核心沃爾瑪渠道，幷在亞馬遜漸進發力。此外，公司在東南亞市場通過配方升級以强化産品差异化，重點推進數字化社群運營，深化電商渠道與本地平台合作，實現了100%增長。全家營養穩步增長，多維築基蓄力遠航作為持續培育的「第二增長曲綫」業務，2025年澳優營養品業務穩步增長，錄得收入同比增長5.2%。公告顯示，收入的增長主要得益於明星菌株和産品的不斷創新、渠道策略的精准實施以及品牌效應的持續釋放。科研驅動品牌發展。澳優與江南大學簽訂六年戰略合作，成立微生態及功能乳聯合創新中心和益生菌協同創新中心，開啓全鏈路創新協同新征程。To B 業務板塊，公司在菌株上實現多項關鍵突破：長雙歧杆菌嬰兒亞種 YLGB-1496 獲國家衛健委批准列入嬰幼兒可食用菌種名單，至此澳優已擁有兩株國家批准的嬰幼兒益生菌菌株，成為中國嬰幼兒益生菌領域的「雙冠王」；自主研發的動物雙歧杆菌乳亞種 CP-9 通過美國 FDA GRAS 認證，標志著澳優在科研創新和質量管控方面達到世界領先水平。菌株技術的持續突破，為品牌發展提供强勁持久的核心動能。2025年，To C業務板塊，NC養胃粉、舒鼻益生菌穩居小紅書品類搜索熱度前列；經歐睿國際認證，NC榮獲「澳洲品牌鼻敏益生菌全國銷量第一」。創新響應新消費需求。葆益常 ® 活性乳酸菌粉以迷你太空艙設計解鎖益生菌産品顔值新高度；添加BL-99 專利菌株的伊利暢適益生菌躋身電商熱銷榜；閃溶粉、微泡片等多元劑型方案，有效提升合作夥伴産品競爭力。NC全年推出G13成長膠囊、恬睡益生菌等17款新品，構建起覆蓋腸胃、鼻敏、睡眠、身高、眼腦、肝腎及女性健康等領域的精准營養矩陣。渠道升級助力業務發展。公司持續深耕藥綫渠道，規模與增速同步提升；深化頭部平台合作，私域電商高速增長；强化明星菌株應用，品牌客戶持續拓展；開拓歐美市場，海外市場空間實現突破。NC在天猫、京東等主流電商穩健增長，養胃、舒鼻系列産品在山姆、中免等渠道成為跨境保健品類目領先品牌；携手XKA、蜂享家布局私域，構建綫上增量矩陣；綫下穩固核心客戶、拓展潜力客群，藥綫試點初見成效，為業務多元發展夯實基礎。國內奶粉業務市占率穩步提升，築牢核心基本盤當前中國嬰配粉行業處于深度調整期，面臨總量收縮、競爭加劇、渠道變革等多重壓力，新生人口基本面與渠道結構持續承壓。公告期內，澳優在行業週期性挑戰中築牢核心基本盤，實現自有品牌奶粉業務市占率穩步提升，錄得整體收入約人民幣53.21億元。據尼爾森IQ及星圖數據，2025年佳貝艾特在中國全渠道羊奶粉市場份額提升2.6個百分點至30.2%。尼爾森IQ數據顯示，佳貝艾特已連續8年（2018年-2025年）在中國進口嬰幼童羊奶粉市場份額超六成，幷經過弗若斯特沙利文研究確認持續穩居「羊奶粉全球銷量與銷售額第一」，彰顯其不可撼動的領頭羊地位。尼爾森IQ數據同時顯示，公司牛奶粉業務穩住市場份額，標志著因前期內部整合與渠道調整帶來的階段性影響全面結束。截至公告發布期，澳優旗下海普諾凱斬獲艾媒諮詢（iiMedia Research）「2025嬰幼兒全面營養奶粉全國銷量第一」及「中國全面營養嬰配奶粉開創者」雙重認證，這也是其連續三年蟬聯全面營養奶粉銷量榜首。2025年，公司順利推進8個系列24款産品新國標2.0注册，完成2個系列6款嬰幼兒配方奶粉、25款調製乳粉開發上市，為消費者提供更多功能化、細分化的産品新選擇。佳貝艾特憑藉《一種有助于免疫調節和緩解免疫應激的嬰幼兒配方奶粉的研究與開發》榮獲「科學技術獎技術進步獎」一等獎，海普諾凱1897獲評「質量百分百産品」，産品力獲權威認可。精益管理提質增效，組織活力持續迸發2025 年，澳優通過充分釋放全球供應鏈勢能、强化內部管理效能、塑造全球協同文化根基、推進數智化體系建設、提升可持續發展治理能力等舉措，持續夯實長遠發展基礎，不斷實現組織效率與發展質量的同步提升。全球供應鏈勢能釋放，開闢價值增長空間。澳優收購荷蘭羊奶酪公司Amalthea Group後，實現核心羊奶粉原料——羊乳清自給自足，幷新增奶酪品類。2025年，公司羊奶酪業務錄得收入10.06億元，進一步挖深國際化戰略護城河。與此同時，公司推出羊奶酪蛋白酶解物、水解羊乳清蛋白粉、羊乳鐵蛋白以及羊初乳粉四大羊原料，其中多款核心羊乳原料實現了全球可商業化應用從無到有的突破，為公司開闢全新的價值增長空間。內部管理效能强化，系統推進穩健經營。2025年，公司存貨减值準備同比减少0.9個百分點；整體資産周轉率持續優化改善，存貨周轉天數下降16天。公司持續推進費用精細化管控，費用率實現顯著優化，同比下降1.4個百分點，其中營銷費用率同比下降2.4個百分點。經營理念全球體系化構建，加强全球戰略協同。為更好地匹配業務發展步伐，强化澳優「全球一盤棋」的戰略協同，澳優正式發布《澳優經營理念（海外版）》。該經營理念由澳優全球60餘位核心管理者通過多輪深度研討共創而成，系統構建了澳優海外業務的核心價值與管理原則，為海外團隊量身打造了文化羅盤與行為基準，為未來業務發展奠定了堅實的思想根基。全鏈路數智化升級，為業務與管理雙向賦能。公司從需求調研、流程設計到落地執行的全環節引入數智化，實現决策可追溯、過程可監控、結果可量化；通過搭建數據中台、智能分析模型等工具，讓數據成為優化管理、支撑業務的核心抓手，從根本上保障業務的持續健康發展。秉持可持續發展理念，積極踐行企業社會責任。公司始終秉持可持續發展的長期願景，積極響應聯合國可持續發展目標，圍繞「更優生活、更優營養、更優環境」三大戰略支點，將可持續發展理念融入運營管理體系及價值鏈各環節。2025年，澳優連續第九年開展「海普諾凱格桑花公益行」、啓動「佳貝愛・孕無憂」孕産婦心理健康公益行等活動，持續在鄉村振興、興教助學、國民營養提升、自然灾害救助等方面持續貢獻企業力量。2025年，依托全球消費者、股東、社會各界的支持及全體員工的奮力拼搏，公司成功抵禦經濟及行業週期性調整帶來的多重挑戰。展望 2026年，內外部環境依然複雜嚴峻，澳優將繼續以消費者為中心，錨定經營目標，加快體系化建設，以創新驅動發展，以管理提升效能，以更優質的産品與業績回饋各方信賴，實現長期可持續高質量發展。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月26日 - (亞太商訊) - 中東局勢持續升級，正深刻影響全球能源與化工供應鏈格局，國內甲醇市場首當其衝迎來價格暴漲，疊加合成氨價格同步上行，國內最大焦爐煤氣制甲醇生產商中國旭陽集團（1907.HK）盈利預期大幅提升，估值修復潛力顯著。 作為中國甲醇進口的主要來源地，中東地區占中國年進口總量70%以上，霍爾木茲海峽通航限制，加大了中國甲醇的供給缺口，導致國內甲醇期、現貨價格大幅攀升，幅度約20%-45%。數據顯示，年初至今，甲醇5月期貨價格由2215元/噸上漲至3089元/噸，漲幅39.5%；現貨河北地區甲醇出廠價自年初上漲600元至2650元/噸，漲幅29.3%。 受益於行業景氣度上行，中國旭陽成為主要贏家之一。據悉，國內焦爐煤氣制甲醇總產能約1600萬噸，中國旭陽甲醇總產能60萬噸，占比4%，包括定州天鷺30萬噸，金牛旭陽20萬噸及呼和浩特旭陽中燃10萬噸，全部為焦爐煤氣制甲醇，全年滿負荷穩定生產運行。與天然氣制甲醇相比，焦爐煤氣制甲醇不僅能有效規避外部供應鏈中斷帶來的衝擊，還具備明顯的生產成本優勢。國內天然氣制甲醇原料氣成本在2300元/噸左右，而焦爐煤氣制甲醇原料氣成本僅1000元/噸，其他費用相對穩定可控。 初步預測，甲醇全年平均價格高於2500元/噸。中國旭陽集團噸醇淨利潤超過600元/噸，同比2025年淨利潤增長將超過2.0億元，全年甲醇板塊淨利潤將超過3億元。 值得注意的是，公司醇氨聯動模式進一步增厚盈利空間。中國旭陽在60萬噸甲醇基礎上，目前已建成65萬噸，利用甲醇工藝尾氣-馳放氣，形成醇氨聯動機制，實現能源綜合梯級利用，是行業內經濟效益最大化的經營模式。合成氨價格自三月份以來，每噸上漲200元至2200元/噸，漲幅10%，疊加傳統春耕旺季的影響，未來價格有望繼續走高，噸利潤將超過300元左右。初步估測，年淨利潤同比增長將超過1.5億元。 從同業對標來看，近期，市場高度關注的甲醇概念股-金牛化工（SH.600722），其控股的金牛旭陽化工，是由旭陽集團全面負責運營管理的聯營公司。得益於中國旭陽集團30多年煤化工管理經驗，以及焦爐煤氣綜合利用領域的成熟技術和高效管理，金牛旭陽自成立以來，為股東和投資者持續創造價值。三月份以來，金牛化工股價最高漲幅超過70%，市值高點突破120億元。參照金牛化工市值表現，按照中國旭陽甲醇60萬噸總規模，中國旭陽集團的價值明顯被低估。 長期來看，中國旭陽運營管理總量約2500萬噸焦炭產能，其穩定的產品質量、供應鏈物流保障能力，以及定製化服務能力，構築穩定的產業鏈關係，也將持續不斷為醇氨板塊提供穩定的原料氣供應保障。短期內，國際甲醇、合成氨供應緊張與價格上漲態勢或將延續，為中國旭陽帶來市場機遇。中長期看，地緣衝突加劇了全球能源供應鏈的不確定性，進一步凸顯中國旭陽產業鏈縱向發展、相關多元化產業協同的重要性和競爭優勢。 業內人士表示，中國旭陽將敏銳研判市場變化，靈活調整經營策略，持續優化醇氨產品的產能配比，充分釋放焦爐煤氣原料的成本優勢，強化在能源價格波動周期中的抗風險能力與盈利能力，為業績持續增長和公司價值提升奠定堅實基礎，其業績增長確定性較強，隨着盈利持續釋放，公司估值有望穩步提升，值得資本市場重點關注。

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 隨著人工智慧加速邁向推理階段，企業級AI迎來規模化落地，Token消耗呈指數級攀升，資料需求進入全新發展階段。在這一趨勢下，高品質、結構化、場景化的專業資料，正成為AI時代企業構建核心戰略競爭能力的關鍵所在。作為中國領先的AI即時資料基礎設施及分析服務商，迅策科技得益于賽道紅利，憑藉全鏈路技術能力與多元增長引擎驅動，正加速確立其在AI資料層的核心地位。隨著智慧經濟新形態的全面展開，這家深耕十年的企業正迎來結構性價值重估的視窗期。Token價值重構：讓每一次資料調用都可量化、可計價迅策科技成立於2016年，歷經十年發展，已構建起覆蓋資料獲取、清洗、標準化、即時計算至大模型調優的全鏈路技術體系。公司以AI Data Agent為核心，專注於毫秒級即時資料處理，服務領域涵蓋金融、城市運營、高端製造、醫療、機器人、衛星、低空經濟、電力、電網及能源等多元化產業。在AI推理時代開啟的當下，Token正從"燃料"進化為"硬通貨"。如何將每一個Token的價值最大化，成為大模型推理階段的核心命題。當前，通用大模型普遍採用"用算力換精度"的策略，每一次推理都伴隨著大量無效Token消耗。一旦推理失敗，前期投入的Token全部作廢——這是通用AI面臨的共同困境。相比之下，垂類AI解決方案則是用行業資料為通用大模型安裝一個"外腦"。其核心在於用業務模型優化推理路徑，提前判斷任務可行性，從源頭避免Token浪費。長期深耕專業垂類資料建模領域的迅策科技，憑藉其多年積累的高品質、場景化垂類資料，相當於為每一次Token調用加裝了"增效器"，在消耗 Token 時換取更高精度的結果，實現最高的產出確定性。更為關鍵的是，公司正在構建全鏈路的資料計量、計費、結算能力，使每一次資料調用，都可量化、可計價，通過提升每單位Token的有效性，為客戶帶來更高的業務價值。圍繞這一思路，迅策科技的平臺採用"樂高式"模組化架構，讓客戶可以根據自身需求靈活組合模組，實現"按需裝配、隨需而變"，建立深度黏性。公司在定價與收費模式上亦遵循靈活設定，基於模組數量、處理速度等維度，銷售採用訂閱制、交易制以及按Token收費制的模式，以精准匹配客戶需求。目前，迅策科技正全力構建全鏈路的資料計量與結算體系，探索按大模型調用次數與模組應用個數等維度計價，讓客戶為"有效Token"付費，而不是為算力消耗買單。業績拐點已現，盈利能力得到驗證在Token價值重構背景與商業模式創新的推動下，迅策科技業績表現強勁，迎來歷史性拐點：2025年下半年，公司實現經調整淨利潤0.5億元，首次實現半年度正向盈利。此外，公司在2025年上半年實現營收1.98百萬元，下半年營收躍升至10.87百萬元，環比激增449%。公司在高速擴張的同時，盈利能力已開始實質性釋放。全年來看，公司實現營業收入達1,284.66億元，較上年同期大幅增長103.28%，成功跨越"十億營收"這一關鍵門檻，標誌著公司已從早期技術驅動的初創階段，正式邁入可規模化複製的平臺化發展新紀元。此外，2025年公司綜合毛利約為人民幣792.08百萬元，較上年度約人民幣484.63百萬元大幅增加63.44%。經調整淨虧損方面，扣除一次性非經常性損益後，公司2025年度經調整淨虧損為人民幣54.84百萬元，較2024年度的82.37百萬元大幅收窄33%。值得注意的是，2025年公司綜合毛利率達62%，不僅高於以AI晶片為核心業務的寒武紀（55%），更遠超通用大模型公司Minimax（25.4%），體現出其在AI資料基礎設施領域獨特的高價值卡位元與商業模式韌性。在研發投入方面，迅策科技亦保持了高效的增長轉化。2025年公司研發開支達450.44百萬元，研發支出占收入比重為48%，驅動營業收入實現105%的同比增長；相比之下，Minimax研發支出占比高達219%，收入增幅為159%。迅策以更低的研發強度，實現了接近同等級別的擴張速度。隨著收入規模持續擴大、新行業毛利逐步收斂，公司短期盈利目標為實現經調整淨利潤迎來拐點。未來隨著已投入行業陸續進入毛利收斂期，以及Token付費與分成模式加速落地，公司淨利率有望加速提升。多元增長引擎驅動，業務結構持續優化業績的強勁增長並非偶然，背後是迅策科技多維驅動、系統推進的增長邏輯。加速跨行業複製。公司目前覆蓋9大行業，對標Palantir的17個行業，橫向拓展空間廣闊。迅策科技正加速向資管、電信、電力、城市管理、高端製造、醫療、能源、機器人訓練平臺、商業航太等國家重點發展的行業縱深拓展。每進入一個新行業，公司先用3-5年完成行業資料沉澱，隨後便可實現同行業客戶的快速複製推廣。商業模式驅動客戶價值深耕。 隨著客戶從單一模組走向多模組部署、從局部試用走向核心業務流程嵌入，ARPU值仍有顯著提升空間。通過Token調用次數、模組應用數量及單次Token價值的協同提升，公司將打開全新的增長空間。穩步開拓海外業務，構建全球化佈局。公司規劃2026年海外收入占比提升至10-15%，2027-2028年持續提升全球化戰略，為長期增長開闢新的空間。構建戰略合作生態，與算力及演算法上下游深度綁定。迅策科技正與國內頭部GPU廠商及大模型公司深度合作，構建"底層算力+上層應用+資料治理"的一站式解決方案，進一步鞏固其在AI資料層的核心地位。開拓前沿應用，搶佔未來產業制高點。從機器人資料平臺到商業航太、低空經濟、電力電網，迅策科技率先將AI基礎設施延伸至對即時性、可靠性要求極高的新興領域，這些對資料即時性、可靠性要求極致的場景，正是公司技術優勢的最佳試金石。公司將持續加大在前沿領域的研發投入，以尖端場景錘煉技術能力，為未來發展開闢高增長、高價值的新賽道。 從資料服務商到AI經濟核心基礎設施，構建深厚競爭壁壘宏觀層面來看，人工智慧資料領域正迎來五大趨勢的深度交匯：AI Agent時代對即時、安全、高品質資料的需求爆發；垂類模型崛起使專業資料成為行業智慧化升級的關鍵要素；Open Claw等新一代AI作業系統將資料介面標準化，迅策科技正成為核心資料Token供應商；Token化付費成為資料要素市場的新範式；資料資產入表政策落地，企業對資料治理的剛性投入需求激增。在這五大趨勢的交匯點上，迅策科技逐步構築起長期發展的堅實底層邏輯。迅策科技不再只是資料基礎設施提供商，而是連接模型、算力、雲廠商的"連接器"與"賦能者"。向上連接模型，向下連接算力，橫向協同雲廠商，最終為客戶提供不可替代的資料價值。公司強調，其與通用大模型公司是天然的上下游合作關係，而非競爭關係。正如GPU廠商與模型公司深度合作一樣，迅策科技的價值在於：客戶使用的模型越多，公司的服務機會越多，為客戶創造的價值也越多。值得關注的是，與市場上僅做資料清洗、或僅做計算引擎的單一模組廠商不同，迅策科技的核心差異在於全流程覆蓋與為結果負責的能力。從資料獲取、清洗、標準化、建模、即時計算，到模型調優，提供端到端解決方案，確保最終輸出給客戶的資料是乾淨的、準確的、即時的、可被模型秒級調用的。同時，公司深度嵌入客戶的私有雲或本地系統，扮演"資料管家"角色，形成極高的客戶粘性與競爭壁壘。目前，公司產品與解決方案擁有超過300多個功能模組，覆蓋從資料基礎設施到上層分析的全場景。2025年，公司的付費客戶活躍量達到230家，客戶留存率高達90%。ARPU值從2024年的272萬元，再大幅提升2025年559萬元，同比增幅超過103%。當演算法走向開源，算力趨於標準化，真正拉開差距的，是資料——尤其是經過深度治理、能夠驅動大模型的行業資料。迅策科技憑藉十年深耕，已在這一領域構建起深厚的護城河。結語從早期私募工具到跨行業的AI資料基建，從"模組供應商"到"Token計價平臺"，迅策科技始終致力於讓資料成為真正可流動、被調用、可驅動決策的稀缺資源。在智慧經濟新形態加速到來的今天，這家公司正站在結構性重估的起點上, 或進入千億市值陣營。它不是任何人的競爭者，而是所有人都需要的合作夥伴。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com